Article Information
vol. 57 no. 5
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 6, 2020
- Accepted January 3, 2021
- Published online May 13, 2021.
Article Versions
- previous version (January 21, 2021 - 06:24).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©The authors 2021 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Sheila K. Patel1,4,
- Jennifer A. Juno2,4,
- Wen Shi Lee2,
- Kathleen M. Wragg2,
- P. Mark Hogarth3,
- Stephen J. Kent2,5 and
- Louise M. Burrell1,5⇑
- 1Dept of Medicine, Austin Health, University of Melbourne, Melbourne, Australia
- 2Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
- 3Immune Therapies Group, Burnet Institute, Melbourne, Australia
- 4Contributed equally
- 5S.J. Kent and L.M. Burrell contributed equally to this article as lead authors and supervised the work
- Louise M. Burrell, Dept of Medicine, University of Melbourne, Lance Townsend Building, Austin Health, Studley Road, Melbourne, Victoria 3084, Australia. E-mail: l.burrell{at}unimelb.edu.au
Funding
State Government of Victoria
Medical Research Future Fund
1175865 and 2002073National Health and Medical Research Council
1149990, 1055214, 145303ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
140100036
Article usage
Altmetrics
Vol 57 Issue 5
Table of Contents
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences
